Asia FX muted, dollar weakens slightly ahead of Fed rate decision
Investing.com - Piper Sandler has initiated coverage of Kalaris (NASDAQ:KLRS) with a Neutral rating and a $3.00 price target. The micro-cap biotech company, currently valued at $48 million, has seen its shares decline by roughly 78% over the past six months. According to InvestingPro analysis, the stock appears slightly undervalued at current levels.
The research firm expressed concerns that preclinical data for Kalaris’s anti-VEGF treatment, TH103, does not sufficiently demonstrate differentiation from standard care options in retinal diseases.
Piper Sandler acknowledged that TH103’s mechanism of action differs from other anti-VEGF treatments such as Eylea, potentially offering higher drug retention and durability, but stated these attributes need confirmation through clinical data.
Initial Phase 1 data for TH103 is expected in Q4 2025, though Piper Sandler noted that interpretation will rely on cross-trial comparison, suggesting a comparator arm would have been beneficial for clearer assessment.
The firm indicated it remains "on the sidelines" until gaining better clarity on TH103’s clinical profile.
In other recent news, Kalaris has been the subject of analyst attention with a focus on its lead product, TH103, aimed at treating neovascular retinal diseases. William Blair has reiterated an Outperform rating for Kalaris, maintaining a positive outlook on the company’s efforts. This follows investor meetings with Kalaris’s management team, including CEO Andrew Oxtoby and CMO Matt Feinsod, M.D., where discussions centered around TH103’s potential advantages over existing treatments. Meanwhile, Leerink Partners has initiated coverage of Kalaris, also rating the stock as Outperform and setting a price target of $20 per share. Leerink Partners emphasized the significant market opportunity for TH103 in addressing unmet needs in the treatment of wet age-related macular degeneration. The investigational therapy is designed to improve upon existing treatments by offering potentially longer-lasting efficacy. These developments reflect a growing interest in Kalaris’s innovative approach to retinal disease treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.